Prognostic factors for the carbohydrate metabolism normalization in patients with type 2 diabetes mellitus and obesity using liraglutide 3.0 mg per day
Background. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are innovative drugs that effectively reduce glycemic levels and overweight in patients with type 2 diabetes mellitus (T2DM). However, the criteria for predicting the hypoglycemic effect of this group of drugs have not been practically...
Guardado en:
Autores principales: | Igor A. Sklyanik, Marina V. Shestakova |
---|---|
Formato: | article |
Lenguaje: | RU |
Publicado: |
"Consilium Medicum" Publishing house
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0674af6e4e5d4dff96fa9366f81bf22f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date
por: Howell R, et al.
Publicado: (2019) -
The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus
por: Marina Vladimirovna Shestakova
Publicado: (2010) -
The associations of incretin hormone concentration with gestational diabetes mellitus
por: Tatiana V. Saprina, et al.
Publicado: (2016) -
Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
por: Campbell RK, et al.
Publicado: (2010) -
Liraglutide ameliorates nonalcoholic fatty liver disease in diabetic mice via the IRS2/PI3K/Akt signaling pathway
por: Yang P, et al.
Publicado: (2019)